DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Trading Up 0.5 %

DRRX stock opened at $0.87 on Monday. The firm has a market cap of $27.01 million, a P/E ratio of -1.43 and a beta of 0.94. DURECT has a 1-year low of $0.52 and a 1-year high of $1.88. The business’s 50 day moving average is $0.98 and its 200-day moving average is $1.25.

Institutional Trading of DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC lifted its holdings in DURECT Co. (NASDAQ:DRRX) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,658 shares during the quarter. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. Institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.